Your Patients Need Arformoterol — Here's How to Help Them Get It

When a COPD patient on Arformoterol tells you they can't fill their prescription, it's more than an inconvenience — it's a clinical concern. Gaps in long-acting bronchodilator therapy can lead to symptom flares, reduced exercise tolerance, and potentially avoidable exacerbations.

Arformoterol (Brovana) occupies a narrow but critical niche as one of only two nebulized LABAs available in the U.S. For patients who rely on nebulized medication delivery, it's not easily substituted. This guide outlines practical steps you and your staff can take to help patients maintain access.

Current Availability: What's Happening

Arformoterol is not in formal shortage per the FDA's drug shortage database as of 2026. The medication continues to be manufactured and distributed through standard pharmaceutical channels. However, patients routinely report difficulty finding it at retail pharmacies.

The disconnect stems from several factors:

• Low dispensing volume: Most chain pharmacies use automated inventory systems that deprioritize low-volume medications. Arformoterol, as a niche nebulizer product, often falls below stocking thresholds.
• Limited manufacturer count: While generic versions exist, the number of active manufacturers remains small compared to more widely prescribed COPD therapies.
• Storage requirements: Arformoterol requires refrigeration, adding complexity for pharmacy inventory management.
• Insurance friction: Prior authorization requirements and step therapy protocols delay fills, sometimes causing pharmacies to return stock before authorization comes through.

For more on the underlying supply dynamics, see our clinical briefing: Arformoterol shortage — what providers need to know in 2026.

Why Patients Can't Find It

Understanding the patient experience helps you intervene more effectively:

• "My pharmacy doesn't carry it": The most common scenario. The medication isn't stocked, not truly unavailable. The patient hears "we don't have it" and assumes there's a shortage.
• "It's on backorder": Sometimes a wholesaler temporarily doesn't have stock. This usually resolves in days, but the patient may be out of medication in the meantime.
• "My insurance won't cover it": Prior authorization denials or step therapy requirements create access barriers that feel like availability problems from the patient's perspective.
• "It's too expensive": Without insurance, Arformoterol ranges from $456 to over $1,000/month. Patients may abandon their prescription rather than pay out of pocket.

What Providers Can Do: 5 Steps

Step 1: Direct Patients to Medfinder

Medfinder for Providers lets you and your patients check which pharmacies in their area currently have Arformoterol in stock. Integrating this into your workflow is simple — you can check availability while the patient is still in the office and send their prescription to a pharmacy you know has it.

This single step eliminates the most common source of frustration: sending a prescription to a pharmacy that doesn't carry the medication.

Step 2: Build a Pharmacy Network

Identify 2–3 pharmacies in your practice area that reliably stock nebulizer medications, including Arformoterol. These are typically:

• Independent pharmacies serving respiratory patient populations
• Specialty pharmacies with pulmonary focus
• Hospital outpatient pharmacies
• Pharmacies near senior living communities

Keep this list accessible to your prescribing staff so it's easy to route prescriptions appropriately.

Step 3: Proactively Manage Prior Authorization

Many commercial plans and some Medicare Advantage plans require prior authorization for Arformoterol. To minimize delays:

• Submit prior authorization at the time of prescribing, not after the patient arrives at the pharmacy
• Include clear documentation of why nebulized delivery is medically necessary (reduced inspiratory flow, inability to coordinate MDI/DPI use, dexterity limitations)
• Document any prior LABA trials if step therapy is required
• Consider using electronic prior authorization (ePA) tools to speed the process

Step 4: Prescribe Generics When Possible

Generic Arformoterol Tartrate inhalation solution is therapeutically equivalent to brand-name Brovana and significantly less expensive:

• Brand Brovana: $456–$1,045/month
• Generic Arformoterol: $66–$125/month at retail, as low as $48 with discount cards

Prescribing generically improves both cost access and pharmacy availability, as some locations may stock generic but not brand.

Step 5: Have a Bridge Plan Ready

For patients who face temporary supply gaps, have a contingency approach:

• Short-term: Increase SABA (short-acting beta-agonist) frequency for symptom management while the LABA supply is resolved
• Alternative LABA: If the gap will last more than a few days, consider a temporary switch to Perforomist (Formoterol, nebulized) or an inhaler-based LABA if the patient can use one
• Mail-order pharmacy: For patients with recurring fill problems, suggest their insurance plan's mail-order option for more reliable 90-day supplies

Alternatives to Consider

When Arformoterol truly isn't accessible, these are the therapeutic alternatives ordered by similarity:

1. Perforomist (Formoterol Fumarate): Nebulized LABA, 20 mcg twice daily — closest substitute for patients who need nebulized delivery
2. Olodaterol (Striverdi Respimat): Once-daily LABA via soft mist inhaler — lower inspiratory effort than DPIs, good for patients who might tolerate an inhaler
3. Salmeterol (Serevent Diskus): Twice-daily LABA via DPI — widely available generic, but requires adequate inspiratory flow
4. Indacaterol (Arcapta Neohaler): Once-daily LABA via DPI — rapid onset, but requires DPI technique

A patient-facing comparison is available at alternatives to Arformoterol.

Workflow Tips for Your Practice

• Check availability before prescribing: A 30-second check on Medfinder can prevent the patient from making a wasted trip.
• Flag nebulizer-dependent patients: In your EHR, flag patients who require nebulized delivery so staff can proactively manage their medication access.
• Set up refill reminders: Encourage patients to request refills at least one week before running out. Arformoterol may take 1–2 business days to order.
• Educate patients on storage: Remind patients that Arformoterol should be refrigerated in the foil pouch. Improperly stored medication may lose effectiveness.
• Track prior authorization status: Follow up on PA requests within 48 hours. Delayed authorizations are a leading cause of fill failures.

Final Thoughts

Arformoterol access challenges are a systems problem, not a shortage problem. The medication exists — it's the pathway from prescription to patient that breaks down. By building a reliable pharmacy network, managing prior authorizations proactively, and using tools like Medfinder for Providers, you can close that gap for your patients.

COPD patients on nebulized therapy are often among your most vulnerable. A little extra effort on the access front can make a meaningful difference in their daily quality of life.

For the clinical supply briefing, see Arformoterol shortage — what providers need to know in 2026.